These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2294819)

  • 41. Guillain-Barré syndrome following immunisation with Haemophilus influenzae type b conjugate vaccine.
    Gervaix A; Caflisch M; Suter S; Haenggeli CA
    Eur J Pediatr; 1993 Jul; 152(7):613-4. PubMed ID: 8354324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants.
    Insel RA; Anderson PW
    J Exp Med; 1986 Feb; 163(2):262-9. PubMed ID: 3484778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies on the combined administration of Haemophilus influenzae type B--diphtheria toxoid conjugate vaccine (PRP-D) and DTP.
    Gordon LK
    Dev Biol Stand; 1986; 65():113-21. PubMed ID: 3549393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine.
    Takala AK; Eskola J; Leinonen M; Käyhty H; Nissinen A; Pekkanen E; Mäkelä PH
    J Infect Dis; 1991 Nov; 164(5):982-6. PubMed ID: 1940479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon-gamma and interleukin-6 augment the human in vitro antibody response to the Haemophilus influenzae type b polysaccharide.
    Peeters CC; Tenbergen-Meekes AM; Heijnen CJ; Poolman JT; Zegers JM; Rijkers GT
    J Infect Dis; 1992 Jun; 165 Suppl 1():S161-2. PubMed ID: 1588155
    [No Abstract]   [Full Text] [Related]  

  • 46. Current status and prospects for some improved and new bacterial vaccines.
    Robbins FC; Robbins JB
    Annu Rev Public Health; 1986; 7():105-25. PubMed ID: 3521639
    [No Abstract]   [Full Text] [Related]  

  • 47. American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines.
    Pediatrics; 1993 Sep; 92(3):480-8. PubMed ID: 8361814
    [No Abstract]   [Full Text] [Related]  

  • 48. In vitro induction of a Haemophilus influenzae type b polysaccharide-specific antibody response in human peripheral blood lymphocytes of individuals recently vaccinated with an oligosaccharide-protein conjugate.
    Peeters CC; Tenbergen-Meekes AM; Heijnen CJ; Poolman JT; Zegers BJ; Rijkers GT
    J Immunol; 1991 Dec; 147(12):4192-9. PubMed ID: 1753096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical experience with Haemophilus influenzae type b conjugate vaccines.
    Mäkelä PH; Eskola J; Peltola H; Takala AK; Käyhty H
    Pediatrics; 1990 Apr; 85(4 Pt 2):651-3. PubMed ID: 2179855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine.
    Eskola J; Käyhty H; Peltola H; Karanko V; Mäkelä PH; Samuelson J; Gordon LK
    Lancet; 1985 May; 1(8439):1184-6. PubMed ID: 2860387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of breast-feeding on antibody response to conjugate vaccine.
    Pabst HF; Spady DW
    Lancet; 1990 Aug; 336(8710):269-70. PubMed ID: 1973970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Matthews H; Vella PP; Ellis RW; Staub JM; Dolan KT; Rusk CM; Calandra GB
    Pediatrics; 1990 Apr; 85(4 Pt 2):676-81. PubMed ID: 2107518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haemophilus influenzae type b.
    Booy R; Moxon ER
    Arch Dis Child; 1993 Apr; 68(4):440-1. PubMed ID: 8503662
    [No Abstract]   [Full Text] [Related]  

  • 55. Immunization of leukemic children with Haemophilus conjugate vaccine.
    Lange B; Jakacki R; Nasab AH; Luery N; McVerry PH
    Pediatr Infect Dis J; 1989 Dec; 8(12):883-4. PubMed ID: 2626288
    [No Abstract]   [Full Text] [Related]  

  • 56. Haemophilus influenzae type b vaccines: lessons for the future.
    Ward JI; Broome CV; Harrison LH; Shinefield H; Black S
    Pediatrics; 1988 Jun; 81(6):886-93. PubMed ID: 3259307
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults.
    Lepow ML; Samuelson JS; Gordon LK
    J Infect Dis; 1984 Sep; 150(3):402-6. PubMed ID: 6332863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haemophilus influenzae type B vaccine in children with sickle cell disease: antibody persistence after vaccination at age one and one-half to six years.
    Marcinak JF; Frank AL; Labotka RL; Rao S; Frisone LR; Yogev R; McVerry P
    Pediatr Infect Dis J; 1991 Feb; 10(2):157-9. PubMed ID: 2062609
    [No Abstract]   [Full Text] [Related]  

  • 59. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Apr; 42(15):296-8. PubMed ID: 8479415
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity.
    Adderson EE; Chisholm N; Halperin SA
    Clin Invest Med; 1991 Aug; 14(4):338-45. PubMed ID: 1782732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.